Comparison of SB2-Infliximab With Originator-Infliximab in the Measurement of Serum Concentrations: A Short Communication-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparison of SB2-Infliximab With Originator-Infliximab in the Measurement of Serum Concentrations: A Short Communication

Published:2021-10 Issue:5 Volume:43 Page:692-695
ISSN:0163-4356
Container-title:Therapeutic Drug Monitoring
language:en
Short-container-title:

Author:

Ward Mark G.,Rosella Ourania,Rosella Gennaro,Martin Catherine,Gibson Peter R.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Pharmacology

Reference5 articles.

1. A systematic review on infliximab and adalimumab drug monitoring: levels, clinical outcomes and assays;Silva-Ferreira;Inflamm Bowel Dis.,2016

2. Therapeutic drug monitoring of anti-tumour necrosis factor-α agents in inflammatory bowel disease;Mitrev;Expert Opin Drug Saf.,2017

3. Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease;Gibson;Aliment Pharmacol Ther.,2020

4. Harmonization of infliximab and anti-infliximab assays facilitates the comparison between originators and biosimilars in clinical samples;Gils;Inflamm Bowel Dis.,2016

5. Serum trough infliximab levels: a comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease;Malickova;Biologicals.,2016

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical utility of C‐reactive protein‐to‐albumin ratio in the management of patients with inflammatory bowel disease;JGH Open;2024-04

2. Application of a Precision‐Dosing Model to a Real‐World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis;The Journal of Clinical Pharmacology;2023-12-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3